To include your compound in the COVID-19 Resource Center, submit it here.

Globetrotting with linaclotide

Why Ironwood picked AstraZeneca to co-develop linaclotide in China

AstraZeneca plc emerged as Ironwood Pharmaceuticals Inc.'s preferred partner for linaclotide in China based on its willingness to support the biotech's rollout of the guanylate cyclase C (GCC; GUCY2C) agonist in the U.S. In a mutually beneficial move, Ironwood's U.S. sales reps will bolster their presence with GI doctors by simultaneously promoting the pharma's Nexium esomeprazole.

FDA approved linaclotide to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in August. Ironwood will co-market the drug as Linzess in the U.S. with Forest Laboratories Inc.

In that 2007 deal, Forest also received exclusive rights to the product

Read the full 984 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers